Literature DB >> 6500507

Hepatitis B markers in United States drug addicts with special emphasis on the delta hepatitis virus.

A Ponzetto, L B Seeff, Z Buskell-Bales, K G Ishak, J H Hoofnagle, H J Zimmerman, R H Purcell, J L Gerin.   

Abstract

Hepatitis B virus and hepatitis delta virus co-infection in drug addicts has been well described in Europe, the latter agent appearing to have been introduced there in the mid-1970's. Currently, similar data are scanty among United States addicts. We therefore reevaluated 99 drug addicts from three different geographic locations in the United States who had participated in a Veterans Administration Cooperative Study between 1972 and 1975. Almost all were asymptomatic, and all had been subjected to liver biopsy because of prolonged aminotransferase abnormalities. Stored sera were tested for antibody to hepatitis delta antigen (anti-HD) by radioimmunoassay and available liver biopsies examined for hepatitis delta antigen (HDAg) by immunofluorescence. Overall, 19.2% were HBsAg positive, 9.1% HBeAg positive, 90% anti-HBc positive and 10.1%, positive for anti-HD. Anti-HD was identified in 42.1% of addicts who were HBsAg positive and in 3.3% who were anti-HBs positive. No correlation was found between HBeAg and anti-HD, but anti-HD was present significantly more frequently in those with chronic active hepatitis than in those with chronic persistent hepatitis. We conclude that hepatitis delta virus infection is common in HBsAg-positive drug addicts in the United States dating back to at least 1972 and probably earlier.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6500507     DOI: 10.1002/hep.1840040603

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Prevalence of hepatitis delta (delta) virus infection. A seroepidemiologic study.

Authors:  K M DeCock; B Jones; S Govindarajan; A G Redeker
Journal:  West J Med       Date:  1988-03

Review 2.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

3.  Prevalence of markers for hepatitis B and hepatitis D in a municipal house of correction.

Authors:  M A Barry; D Gleavy; K Herd; P J Schwingl; B G Werner
Journal:  Am J Public Health       Date:  1990-04       Impact factor: 9.308

4.  Epidemiology of hepatitis delta virus (HDV) infection.

Authors:  A Ponzetto; B Forzani; P P Parravicini; C Hele; A Zanetti; M Rizzetto
Journal:  Eur J Epidemiol       Date:  1985-12       Impact factor: 8.082

5.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.

Authors:  H Hagan; D C Jarlais; S R Friedman; D Purchase; M J Alter
Journal:  Am J Public Health       Date:  1995-11       Impact factor: 9.308

6.  Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Authors:  Parag Mahale; Peter V Aka; Xiaohua Chen; Ping Liu; Benjamin J Fram; Alan S Wang; Scott Simenel; Fan-Chen Tseng; Sabrina Chen; Brian R Edlin; Jeffrey S Glenn; Thomas R O'Brien
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

7.  Introduction of hepatitis delta virus into Polish drug community.

Authors:  T Laskus; M Radkowski; E Lupa; J Cianciara; J Slusarczyk; G Halama; A Horban
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

8.  Prevalence of hepatitis B infection in long-stay mentally handicapped adults.

Authors:  F Asensio; J M Bayas; M J Bertran; M A Asenjo
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

9.  HBV, HDV and HIV infections in 242 drug addicts: two-year follow-up.

Authors:  C Mandelli; M Cesana; P Ferroni; G P Lorini; G P Aimo; A Tagger; P A Bianchi; D Conte
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

10.  Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?

Authors:  Ben L Da; Farial Rahman; Walter C Lai; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Am J Gastroenterol       Date:  2021-01-01       Impact factor: 12.045

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.